8/102 sources · 2 publishersUpdated Oct 8, 15:40 UTC
Arvinas to present Phase 1 biomarker and oculomotor data for ARV‑102 at the 2026 MDS Congress
Arvinas announced that it will share novel Phase 1 trial results for its oral PROTAC LRRK2 degrader ARV‑102 at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul. The late‑breaking session will feature both oral and e‑poster presentations of biomarker and oculomotor findings from patients with Parkinson’s disease. The presentations are scheduled for Wednesday, October 7, 2026.
Why it matters
The data release could shape investor sentiment toward ARV‑102 and the company’s neurodegenerative pipeline, as market participants assess the early efficacy signals. No analyst commentary was provided in the materials.
Key facts
- 1The presentations will be held at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, Korea, from October 4‑8, 2026. globenewswire.com
- 2The oral presentation is in Session 12, titled “Late‑Breaking Abstracts: Parkinson's Disease,” scheduled for Wednesday, October 7, 2026, from 12:30 – 13:30 ET. globenewswire.com
- 3The oral presentation will be five minutes long and is assigned Presentation Number LBA 15, Order 3. globenewswire.com
- 4An e‑poster of the same abstract (LBA 15) will also be available online. globenewswire.com
- 5ARV‑102 is an orally bioavailable PROTAC designed to cross the blood‑brain barrier and degrade leucine‑rich repeat kinase 2 (LRRK2). globenewswire.com
- 6The data to be presented include biomarker and oculomotor results from the Phase 1 trial in Parkinson’s disease patients. investing.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.